The Mucosal Healing Efficacy And Safety Of Infliximab In The Treatment Of Crohn’s Disease:a Meta-Analysis

PURPOSE:To assess the mucosal healing efficacy and safety of Infliximab in the treatment of the Crohn’s disease.METHODS:Information up to March2014was retrieved from PubMed, Cochrane Library, and Embase, CNKI, VIP, CBM. Collected publications were all about randomized controlled trials (RCTs) of IFX with other drugs. Evaluated the quality of the the included studies were independently performed by two reviewers and performed Meta-analysis by using RevMan5.2software. By changing the fixed effect model and random effect model analysis to assess the sensitivity analysis.RESULTS:5RCTs with a sample403size of patients, the meta-analysis showed that:the short-term mucosal healing with IFX for CD [OR=13.05,95%CI (2.39,71.30), P=0.003] and the long-term mucosal healing[OR=3.28,95%CI (1.97,5.84), P<0.0001] were better in the treatment group than in the control group, the difference was statistically significance. The adverse effects, serious adverse effect, infection were no significantly difference compared with control group. The infusion reaction was a little more common in infliximab versus control group [OR=3.12,95%CI (1.94,5.04),P<0.0001].CONCLUSION:In patients with moderate-to-severe CD, infliximab is effective for the mucosal healing. The infusion reaction was a little more common in infliximab versus control group, while the dverse events and serious adverse events are equal to the traditional medicine.